...a professor at Massachusetts Institute of Technology and a co-founder of Epizyme Inc. (NASDAQ:EPZM) and Idun Pharmaceuticals Inc....

...in liver transplant recipients with reestablished fibrosis. Conatus gained emricasan through its acquisition of the Idun...

...in liver transplant recipients with reestablished fibrosis. Conatus gained emricasan through its acquisition of the Idun...

...in liver transplant recipients with reestablished fibrosis. Conatus gained emricasan through its acquisition of the Idun...

...in liver transplant recipients with reestablished fibrosis. Conatus gained emricasan through its acquisition of the Idun...

...in liver transplant recipients with reestablished fibrosis. Conatus gained emricasan through its acquisition of the Idun...

...in liver transplant recipients with reestablished fibrosis. Conatus gained emricasan through its acquisition of the Idun...

...transplant due to HCV infection this half. Conatus gained emricasan through the acquisition of the Idun...

...transplant due to HCV infection this half. Conatus gained emricasan through the acquisition of the Idun...

...treat chronic liver failure in 2H14. Conatus gained emricasan through its 2010 acquisition of the Idun Pharmaceuticals Inc....